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Available online 20 October 2016Effects of human tribbles homolog 3 (TRIB3) genetic variation (c.251 A N G, Gln84Arg, rs2295490) on the clinical
outcomes of vascular events has not been evaluated in patients with type 2 diabetes after blood pressure lower-
ing and glucose controlling treatment.Wedid an analysis of a 2 × 2 factorial (glucose control axis and blood pres-
sure lowering axis) randomized controlled clinical trial at 61 centers in China, with a follow-up period of 5 years.
The major vascular endpoints were the composites of death from cardio-cerebral vascular diseases, non-fatal
stroke and myocardial infraction, new or worsening renal and diabetic eye disease. A total of 1884 participants
were included in our research with a 4.8 years median follow-up. For glucose lowering axis, patients with
TRIB3 (rs2295490) AA (n = 609) genotype exhibited signiﬁcantly reduced risk of major vascular events com-
paredwith AG+GG (n=335) genotype carriers (Hazard ratio 0.72, 95% CI 0.55–0.94, p=0.016), Paradoxically,
the risk of vascular events were signiﬁcantly increased in patients with AA (n = 621) compared to AG + GG
(n = 319) genotype for intensive glucose control (Hazard ratio 1.46, 95% CI, 1.06–2.17, 35 p = 0.018). For
blood pressure lowering axis, marginally signiﬁcant difference was found between TRIB3 variant and coronary
events. Our ﬁndings suggest that good glucose and blood pressure control exhibited greater beneﬁts on vascular
outcomes in patients with TRIB3 (rs2295490) G allele.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Recently, China faces an increasing burden of type 2 diabetes and its
vascular complications with approximately 11.6% of overall prevalence
in adults (Xu et al., 2013). Peoplewith diabetes impose about 3.38 times
higher cost than those with normal glucose intolerance, while the cost
will be 3.75 times higher for patients with longer duration of diabetes
(≥10 years) compared with those with shorter duration (≤5 years)
due to its complications (Yang et al., 2012). Therefore, it's important
to conduct precise strategies to treat patients with diabetes effectively.
Actually, clinical trials demonstrated thatmore intensive blood pressure
lowering and glucose control yielded evident clinical beneﬁts for diabe-
tes patients with vascular endpoints (Zoungas et al., 2014).
On the other hand, inter-individual variation of drug response was
observed in prophylactic medications for diabetes and its comorbiditiesh Institute, Institute of Clinical
th University, No.110, Xiangya
. This is an open access article under(Tkac, 2015), which may be partially explained by accumulating the
pharmacogenetics evidence. However, the inﬂuence of common genetic
variations on the individual difference in drug response or clinical end-
points need to be conﬁrmed by large and long-term follow-up studies,
because of the progressive feature of type 2 diabetes mellitus (T2DM),
and the mechanisms in molecular levels that related to clinical hetero-
geneity phenotype remains unclear.
Human tribbles homolog 3 (TRIB3, also called NIPK, SINK, TRB3, SKIP3)
is a pseudokinase that can inhibit Akt byphysically occupying its phosphor-
ylation sites, which plays a pivotal role on subsequent insulin signaling (Du
et al., 2003). Previous reports indicated that TRIB3 has a ubiquitous cellular
functions by interacting with a host of molecules establishing a mechanic
link between metabolic phenotypes and cardiovascular risk traits (Wang
et al., 2012; Ti et al., 2011), renal diseases (Dinget al., 2014), tumorprogres-
sion (Hua et al., 2015) in T2DM. Interestingly, in vitro study data showed
TRIB3 genetic variation (c.251 A N G, Gln84Arg, rs2295490) does not affect
its protein level, but impacts on insulin-stimulated Akt (Thr308, Ser473)
and eNOS (Ser1177) phosphorylation, which results in 2 to 3 times of de-
creased eNOS activity and nitric oxide production (Andreozzi et al.,
2008). On another hand, valsartan (an antihypertensive drug), couldthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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prove the cardiac functions in rats with diabetic cardiomyopathy (Zhang
et al., 2006). Moreover, The presence of the gain-of-function mutation in
TIRB3(rs2295490) is one of a leading cause of TRIB3 over-activity and sub-
sequent Akt inhibition, which has linked to increased risk of cardiovascular
diseases by metabolic syndrome, endothelial and/or cardiac dysfunction
(Prudente et al., 2012). Therefore, we considered that TRIB3 may have an
impartible role inmediating the development of the diabetic vascular com-
plications by regulating insulin signal transduction pathway and (or) by
regulating blood pressure homeostasis in patients with type 2 diabetes.
And the relationship between TRIB3 genetic variation and diabetes and its
vascular complications merits further attention.
The achievement of therapeutic goals for plasma glucose, lipid and
blood pressure levels is important to decrease the vascular diseases
risk in patients with diabetes (Li et al., 2015). Although some evidence
showed that a common TRIB3 genetic variation (rs2295490) was a
risk factor for diabetic nephropathy, atherosclerosis, and coronary ar-
tery disease (Prudente et al., 2005; De Cosmo et al., 2007; Formoso et
al., 2011; Gong et al., 2009), some low-frequency genetic variants,
which are detected by re-sequencing of TRIB3, can partially account
for cardiovascular clinical outcomes in diabetes (Prudente et al.,
2015). However, systematical study on the relationship between
TRIB3genetic variant (rs2295490) and antidiabetic or antihypertensive
drug response, vascular complications, especially in a large and long-
term follow-up T2DM clinical trial cohort have not been reported. The
aim of this study is to explore the effects of TRIB3 genetic variation
(rs2295490) on the clinical outcomes of vascular events after blood
pressure lowering and glucose controlling treatment.
2. Methods
2.1. Patients
We conducted a retrospective study on the cohort fromAction in Di-
abetes and Vascular disease: preterAx and diamicroN-MR ControlledFig. 1. Outline of DNA sample collection, randomizaEvaluation (ADVANCE) clinical trial at 61 centers in China, with a fol-
low-up period of 5 years. Approval to conduct the trial was obtained
from the ethics committee of each study center, and all participants pro-
vided written informed consent (registration number NCT00145925).
Detailed rationale, design, follow-up schedule and clinical endpoints of
ADVANCE trial have been described in previous studies (ADVANCE
Management Committe, 2001a, 2001b). In brief, it was a 2 × 2 factorial
randomized controlled trial. Patients with type 2 diabetes were ran-
domly assigned (1:1) to receive perindopril-indapamide or matching
placebo for blood pressure lowering, and modiﬁed-release gliclazide
based intensive or local standard therapy for glycaemic control. For
blood lowering cohort, participants were treated for 6 weeks as run-in
periodwith combination of perindopril and indapamide, then randomly
grouped into ﬁxed combination regimen (perindopril/indapamide, ini-
tially 2.0/0.625mg daily, increasing to 4.0/1.25mgdaily after 3months)
or matching placebo. For glucose controlling group, an open label, ran-
domized protocol was implemented to an intensive glucose control or
to local standard therapy based on local guidelines. The intensive glu-
cose control was deﬁned as the use of gliclazide modiﬁed release
based regimen (30–120 mg daily) and other oral agents, then insulin
aiming for a hemoglobin A1c (HbA1c) value of 6.5% or lower. The local
standard treatment was deﬁned as the patients who continue with
their usual glucose control regimens, which may include any therapy
except the use of gliclazide.
The major vascular endpoints include death from cardio-cerebral
vascular diseases, nonfatal stroke or nonfatal myocardial infraction,
and new or worsening renal or diabetic eye disease. Other vascular
events such as cerebrovascular events (include deathdue to cerebrovas-
cular disease, stroke, transient ischemic attack, and subarachnoid hem-
orrhage), coronary events (include myocardial infarction, angina
pectoris, myocardial ischemia, and sudden death), heart disease (coro-
nary heart disease, heart failure, atrial ﬁbrillation), new or worsening
microalbuminuria, and visual deterioration were also evaluated both
jointly and separately. In our study, therewas noother pre-speciﬁed cri-
terion for the levels of blood pressure, HbA1c or other baseline clinicaltion, and follow-up information of participants.
Table 1
Baseline characteristics of all participants in the subgroup according to TRIB3 (251, A N G) genotype in the blood pressure lowering or glucose controlling groups.
Variable Active drug (n = 934) Placebo (n = 950) Intensive control
(n = 940)
Standard control
(n = 944)
AA AG/GG AA AG/GG AA AG/GG AA AG/GG
Age (years), mean (SD) 65(6) 65(5) 65(6) 64(6) 65(6) 65(6) 65(6) 65(6)
Male, n (%) 299(49) 165(51) 342(55) 163(50) 315(51) 152(48) 326(54) 176(53)
Duration of diabetes† (years), median (IQR) 7(3‐11) 7(3–11) 7(3–11) 7(3−12) 7(3–12) 7(3–11) 7(3–11) 7(3–12)
Previous vascular disease
History of major macrovascular disease, n (%) 109(18) 60(18) 120(19) 67(20) 117(19) 60(19) 112(18) 67(20)
History of myocardial infarction, n (%) 23(4) 9(3) 24(4) 13(4) 22(4) 9(3) 25(4) 13(4)
History of stroke, n (%) 90(15) 51(16) 103(17) 56(17) 102(16) 52(16) 91(15) 55(16)
History of major microvascular disease, n (%) 80(13) 52(16) 91(15) 39(12) 78(13) 46(14) 93(15) 45(13)
History of macroalbuminuria ‡, n (%) 46(8) 26(8) 52(8) 21(6) 44(7) 22(7) 54(9) 25(8)
History of microvascular eye disease§, n (%) 37(6) 30(9) 44(7) 21(6) 38(6) 27(9) 43(7) 24(7)
Blood pressure assessment
Systolic blood pressure (mm Hg), mean (SD) 140(21) 139(22) 141(22) 138(19) 140(21) 137(21) 141(21) 140(21)
Diastolic blood pressure (mm Hg), mean (SD) 79(11) 78(11) 79(11) 78(10) 79(11) 78(11) 79(11) 77(11)
History of currently treated hypertension, n (%) 390(64) 216(66) 396(64) 211(64) 389(63) 212(67) 397(65) 215(64)
Blood glucose assessment
Glycated hemoglobin (%), mean (SD) 7.7(1.8) 7.8(1.8) 7.7(1.7) 7.6(1.8) 7.7(1.8) 7.8(1.9) 7.7(1.8) 7.7(1.8)
Fasting plasma glucose (mmol/l), mean (SD) 8.7(3.0) 9.0(3.3) 8.5(2.8) 8.7(2.9) 8.7(3.0) 8.9(3.2) 8.5(2.8) 8.8(3.1)
Other major risk factors
Current smokers, n (%) 139(23) 73(22) 158(25) 71(22) 150(24) 69(22) 147(24) 75(22)
Total cholesterol (mmol/L), mean (SD) 5.4(1.2) 5.4(1.2) 5.3(1.2) 5.3(1.3) 5.4(1.2) 5.4(1.3) 5.4(1.2) 5.2(1.2)
High-density lipoprotein (mmol/L), mean (SD) 1.3(0.5) 1.3(0.5) 1.3(0.5) 1.3(0.5) 1.3(0.5) 1.3(0.5) 1.3(0.5) 1.3(0.5)
Low-density lipoprotein (mmol/L), mean (SD) 3.3(1.0) 3.2(1.0) 3.2(1.0) 3.2(1.1) 3.2(1.1) 3.3(1.1) 3.2(1.0) 3.1(1.0)
Triglyceride (mmol/l), mean (SD) 2.0(1.6) 2.1(1.5) 2.0(1.5) 2.0(1.4) 1.9(1.4) 2.2(1.7) 2.1(1.7) 1.9(1.2)
Urinary albumin:creatinine ratio (mg/mmol), median (IQR) 2.4
(1.1–7.5)
2.3
(1.2–8.1)
2.5
(1.1–6.7)
2.4
(1.1–6.2)
2.4
(1.2–7.0)
2.6
(1.1–8.0)
2.4
(1.1–7.0)
2.1
(1.1–6.9)
Body-mass index (kg/m2), mean (SD) 25(3) 25(3) 25(3) 25(3) 25(3) 25(3) 25(3) 25(3)
†Durations of diabetes are shown as the age at ﬁrst visitminus agewhen diabetes ﬁrst diagnosed. ‡Urinary albumin-creatinine ratio N 33.9mg/mmolwas deﬁned asmacroalbuminuria. §
Proliferative diabetic retinopathy, retinal photocoagulation therapy, macular oedema, or blindness related to diabetes are deﬁned as microvascular eye diseases.
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were successfully genotyped in TRIB3 (rs2295490) by Sanger
sequencing.
2.2. Genotyping Procedure for TRIB3
Genotyping of TRIB3 rs2295490 was determined by PCR-direct se-
quencing. The PCR primers for TRIB3 (rs2295490) were as follows: the
sense primer, 5′GTTGCCCCTGA-GCCCACCTACT3′; and the antisenseFig. 2. Effects of TRIB3 (rs2295490) genetic variation on HbA1c (%) levels at baseline and durin
mean ± SEM, p-values were estimated from stepwise linear regression model with adjustmen
drug dosage between TRIB3 (rs2295490) AA and AG+ GG genotypes at the visit time.primer, 5′TCCCTGGATGCTTCCCCACTAA3′, with a production length of
286 bp. The reaction mixture (25 μl) contained: 10× PCR buffer
(2.5 μl), 10× dNTP (2.5 μl), 10 μM of each of the sense and antisense
primers (0.5 μl), H2O (16.8 μl), g - DNA (2 μl), Taq-ase (0.2 μl). Temper-
ature cyclingwas proceeded as follows: initial denaturation for 5min at
94 °C, followed by 36 cycles of 30 s at 94 °C, annealing at 57 °C for 30 s,
and elongation at 72 °C for 30 s, and a terminal extension for 5 min. Ge-
notypes were determined without knowledge of the status of patients
and 10% blinded. Random DNA samples from the patients wereg follow-ups between intensive and standard glucose control groups. Data are shown as
t for sex, age, duration of the disease, body mass index (BMI), combined medication and
184 F. He et al. / EBioMedicine 13 (2016) 181–189genotyped twice with 100% concordance. Sequencing was assisted by
Shanghai Majorbio Bio-pharmTechnology Company.
2.3. Statistical Analysis
All the analyses were performed with SPSS (version 20.0 for win-
dows; Chicago, IL). Allele frequencies were determined by the geno-
types of all the participants. Continuous data are presented as mean
values ± SD, and frequencies or percentages are for categorical vari-
ables. The Hardy–Weinberg equilibrium analysis was carried out for
the study participants using the χ2-test. Differences in baseline charac-
teristics among the phenotypes were assessed by independent-samplesFig. 3. Effects of TRIB3 (rs2295490) genetic variation on the cumulative hazard function of clini
death from cardiovascular disease, stroke ormyocardial infraction, andneworworsening renal o
due to cerebrovascular disease, stroke, transient ischemic attack, and subarachnoid hemorrhag
and sudden death). Vertical broken lines indicate additional information on microvascular eve
month visits. And the event times were recorded as the visit dates. The curves were trunc
between TRIB3 (rs2295490) AA and AG + GG genotypes (hazard ratios and p-values) were e
available data.t-test or Wilcoxon rank sum test, appropriately. General linear model-
multivariate ANOVA and linear regression analysis was performed in
plasma glucose, lipid levels and blood pressure between TRIB3
(rs2295490) AA, AG+GG genotypewith adjustment for sex, age, dura-
tion of the disease, body mass index (BMI), combined medication and
drug dosage. Cox backword (LR: entry p = 0.05 and removal p =
0.10) regression model adjustment by history of vascular disease, base-
line of the clinical biochemical data, sex, age, duration of the disease,
combinedmedication and drug dosagewas used to investigate the rela-
tionship between genetic variation and the risk of clinical outcomes of
vascular event endpoints. A two-tailed P-value b 0.05 was considered
signiﬁcant.cal endpoints according to glucose control strategy. The major vascular endpoints include
r diabetic eye disease. Other vascular events such as cerebrovascular events (include death
e), coronary events (include myocardial infarction, angina pectoris, myocardial ischemia,
nts (diabetes related nephropathy and retinopathy) were obtained at 24-month and 48-
ated at Month 57, by which time 99% of events had occurred. The effects of treatment
stimated from survival-cox regression models with backward LR adjustment for baseline
185F. He et al. / EBioMedicine 13 (2016) 181–1893. Results
3.1. Genotyping and Characteristics of Patients
A total of 1898 Chinese participants were enrolled fromMay 2002 to
December 2002 in ADVANCE trial (China centers) from 61 hospitals,
with an median of 4.8 years follow-up duration in 1714/1884 (91.0%)
participants who were successfully completed at scheduled end of fol-
low-up (Fig. 1), and 1884/1898 (99.3%) of DNA samples from these pa-
tients passed quality control for genotyping of TRIB3 (rs2295490).
Genotyping data of TRIB3 (rs2295490) in our study cohort showed a
minor allele (G) frequency of 17.1%, the (AA, AG and GG) genotype fre-
quencies were 1230/1884 (65.3%), 581/1884(30.8%) and 73 (3.9%), re-
spectively, which were in Hardy-Weinberg equilibrium across the
randomized groups (Table S1 in the Supplementary Appendix). No sig-
niﬁcant difference was observed across the baseline characteristics atFig. 3 (contentry between AA and AG + GG genotype of TRIB3 (rs2295490) in
blood pressure lowering or glucose controlling axis (Table 1).
3.2. Glucose Controlling Axis
For the intensive glucose controlling group, the mean glycosylated
HbA1c levelwas 6.8% throughout the follow-up period, and itwas higher
in patients with AG + GG genotypes (6.7%) compared to AA genotype
(6.6%) after a follow-up of 6 months, while the difference observed
was not signiﬁcant until the period between 15 and 30 months (AA vs
AG + GG, 6.6% vs 6.8%) (Fig. 2a). For the standard glucose control
group, themean glycosylatedHbA1c levelswas 7·4% throughout the fol-
low-up period, and it showed no signiﬁcant difference between AA and
AG + GG genotypes (AA vs AG + GG, 7.4% vs 7.4%) after randomized
treatment (Fig. 2b). Additionally, in the intensive and standard glucose
treatment groups, fast plasmid glucose and HbA1c levels between AAinued).
Fig. 3 (continued).
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cant (data not shown).
A total of 458 patients had major macrovascular or microvascular
events during the visits: 152/621 (24.5%) patients with AA genotype
and 61/319 (19.1%) with AG + GG genotype (hazard ratio, 1.46; 95%
CI, 1.06 to 2.17; p=0.018) were observed in the intensive glucose con-
trol group (Fig. 3a); 143/609 (23.5%) patients with AA genotype and
102/335 (30.4%) with AG + GG genotype (hazard ratio, 0.72; 95% CI,
0.55 to 0.94; p= 0.016) were observed in the standard glucose control
group (Fig. 3b). Additionally, TRIB3 (rs2295490) genetic variation
showed an inverse effect on the major macrovascular events (Fig. 3c
and d) and microvascular events (Fig. 3e and f) when compared be-
tween the two groups, and the effects on the secondary clinical out-
comes of coronary (Fig. 3g and h) and cerebrovascular events (Fig. 3i
and j) are similar as well. There was no signiﬁcant difference in other
major and secondary macrovascular or microvascular events whenTable 2
Effects of TRIB3 (c.251, A N G) genetic variation on patients with major and secondary outcom
Subgroup Intensive, n (%)
AA AG + GG
Major clinical outcomes
Combined major macro- and micro-vascular events 152(24.5) 61(19.1)
Major macrovascular events 89(14.3) 39(12.2)
MI 14(2.3) 7(2.2)
Stroke 60(9.7) 28(8.8)
Death from Cardio-cerebral vascular cause 27(4.3) 8(2.5)
Major microvascular events 75(12.1) 28(8.8)
New or worsening nephropathy 28(4.5) 9(2.8)
New or worsening retinopathy 57(9.2) 21(6.6)
Secondary clinical outcomes
Coronary events 69(11.1) 22(6.9)
Heart disease 76(12.2) 29(9.1)
Cerebrovascular events 68(11.0) 31(9.7)
All macrovascular events 144(23.2) 63(19.7)
Visual deterioration 127(20.5) 56(17.6)
New or worsening microalbuminuria 23(3.7) 17(5.3)
All microvascular events 211(34.0) 90(28.2)
Death from any cause 45(7.2) 14(4.4)
Neuropathy 29(4.7) 11(3.4)
HR=Hazard Ratio, the effects of treatment between TRIB3 (c. 251, A NG)AA andAG/GG genoty
backward LR adjustment for baseline available data.analyzed jointly or separately, except for the secondary clinical end-
points of new or worsening microalbuminuria and death from any
cause (Table 2).
3.3. Blood Pressure Controlling Axis
Over the duration of follow-ups, the mean systolic blood pressure
(SBP) was 132.8 mm Hg and diastolic blood pressure (DBP)
74.6 mm Hg in perindopril–indapamide ﬁx tablet treatment group;
while the mean SBP was 137.8 mmHg and DBP 76.9 mmHg in placebo
matching treatment group. In the randomized active blood lowering
treatment group, compared with TIRB3 (rs2295490) AA genotype car-
riers, patients with AG + GG genotype had a mean decrease of DBP of
0.8 mm Hg. Marginally signiﬁcant difference (p= 0.063) between the
two groups at the end of follow-up was observed (Fig. 4a). Conversely,
in matched placebo treatment group, the mean DBP was increased byes according to glucose-control strategy.
HR (95% CI), P-value Standard n (%) HR (95% CI), P-value
AA AG + GG
1.46(1.06–2.17), 0.018 143(23.5) 102(30.4) 0.72(0.55–0.94), 0.016
1.28(0.86–1.90), 0.22 73(12.0) 57(17.0) 0.66(0.46–0.96), 0.028
0.91(0.34–2.46), 0.86 13(2.1) 13(3.9) 0.47(0.21–1.04), 0.061
1.14(0.72–0.82), 0.57 55(9.0) 40(11.9) 0.70(0.45–1.06), 0.093
2.27(0.91–5.65), 0.078 21(3.4) 13(3.9) 0.78(0.33–1.84), 0.57
1.62(1.02–2.58), 0.040 86(14.1) 55(16.4) 0.81(0.56–1.15), 0.24
1.57(0.70–3.54), 0.27 36(5.9) 25(7.5) 0.77(0.44–1.34), 0.35
1.65(0.97–2.82), 0.065 57(9.4) 36(10.7) 0.924(0.60–1.43), 0.72
1.80(1.09–2.98), 0.023 65(10.7) 42(12.5) 0.90 (0.60–2.60), 0.61
1.42(0.91–2.21), 0.12 80(13.1) 50(14.9) 0.91(0.64–1.29), 0.60
1.19(0.77–1.85), 0.43 48(7.9) 41(12.2) 0.61(0.40–0.93), 0.023
1.26(0.93–1.71), 0.14 128(21.0) 85(25.4) 0.82(0.61–1.09), 0.16
1.14(0.83–1.57), 0.42 87(14.3) 46(13.7) 1.03(0.71–1.49), 0.88
0.60(0.32–1.15), 0.12 36(5.9) 11(3.3) 2.23(1.08–4.60), 0.030
1.25(0.97–1.62), 0.079 188(30.9) 99(29.6) 1.06(0.82–1.36), 0.66
1.96(1.02–3.75), 0.044 34(5.6) 22(6.6) 0.86(0.48–1.54), 0.62
1.35(0.67–2.73), 0.41 24(3.9) 11(3.3) 1.28(0.60–2.70), 0.53
pes (hazard ratios and p-values)were estimated from survival-cox regressionmodelswith
Fig. 4. Effects of TRIB3 (rs2295490) genetic variation on diastolic blood pressure response and coronary clinical outcomes during follow-up between perindopril/indapamide and placebo
treatment groups. Data of Panel a and b are shown as mean± SEM, p-values were estimated from stepwise linear regression model with adjustment for sex, age, duration of the disease,
bodymass index (BMI), combinedmedication and drug dosage between TRIB3 (rs2295490) AA and AG+ GG genotypes at the visit time. Coronary events include myocardial infarction,
angina pectoris, myocardial ischemia, and sudden death. The effects of treatment on coronary events between TRIB3 (rs2295490) AA andAG+GGgenotypes (hazard ratios and p-values)
were estimated from survival-cox regression models with backward LR adjustment for baseline available data (panel c and d).
187F. He et al. / EBioMedicine 13 (2016) 181–1891.0 mm Hg respectively (Fig. 4b). However, SBP presented no remark-
able difference between the AA and AG+GG groups (data not shown).
For blood pressure lowering axis, there was no signiﬁcant effect of
TRIB3 (rs2295490) genetic variation on the risk of any major and sec-
ondary clinical outcomes between the active and placebo treatment
groups (Table S2 in the Supplementary Appendix). However, it is
worth noting that the genetic variation was weakly correlated to the
risk of total coronary events in the active treatment group (hazard
ratio, 1.52; 95% CI, 0.98 to 2.35; p = 0.061) (Fig. 4c), but not in the
matched placebo treatment group (hazard ratio, 1.04, 95% CI, 0.67 to
1.02; p= 0.85) (Fig. 4d).
4. Discussion
For the intensive glucose control axis, as data shown in Fig. 2, TRIB3
(rs2295490) genetic variation had a signiﬁcant inﬂuence on patients
thatwere assigned to the intensive glucose control group, but not on pa-
tients assigned to the standard glucose control group. For the intensive
glucose control group, the gliclazideMR-based, alongwith othermainly
prescribed drugs such asmetformin, insulin preparationswere requiredto make the glycated hemoglobin value target to 6.5% or lower. For the
standard glucose control group, however, a routine administration of
metformin and sulphonylureas (except gliclazide) glucose control strat-
egies was recommended. Themain difference in the clinical medication
between the two groupswas that the proportion of insulin combination
treatment. Interestingly, TRIB3 is a pseudo-kinase that plays a pivotal
role in the insulin signaling transduction pathway (Du et al., 2003),
and TRIB3 (rs2295490) G allele can lead to a gain-of-function amino
acid substitution in the insulin target tissues (Liew et al., 2010). In addi-
tion, the genetic variation dose not directly affect fast blood glucose
levels, but by altering the interplay between insulin sensitivity and se-
cretion (Prudente et al., 2010), our results were in accordance with
these ﬁndings.
Besides, our data showed that TRIB3 (rs2295490) genetic variation
had a signiﬁcant clinical relevance to macrovascular or microvascular
clinical outcomes.Wewere surprised to ﬁnd that TRIB3 (rs2295490) ge-
netic variation played a reverse role between intensive and standard
glucose control groups (Fig. 5). Subgroup analysis further conﬁrmed
that patients with G allele had greater beneﬁts in the macrovascular
and microvascular events from patients with intensive glucose
Fig. 5. Analysis of TRIB3 (rs2295490) genetic variation and treatment-speciﬁc interaction
in glycaemic control arm. Vertical broken lines indicate additional information on
microvascular events (diabetes related nephropathy and retinopathy) were obtained at
24-month and 48-month visits. And the event times were recorded as the visit dates.
The curves were truncated at Month 57, by which time 99% of events had occurred. The
effects of TRIB3 (rs2295490) genotypes and treatment-speciﬁc interaction in glycaemic
control arm (hazard ratios and p-values) were estimated from survival-cox regression
models with backward LR adjustment for baseline available data.
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vascular and all coronary clinical outcomes (Fig. 3e and g). For the pa-
tients in the standard glucose control group, however, the G allele was
a risk factor of major macrovascular and cerebrovascular clinical out-
comes (Fig. 3d and j). Our sub-center data illustrated that the incidence
ofmajormicrovascular eventswas signiﬁcantly reduced in the intensive
glucose controlwhen comparedwith the standard glucose control (haz-
ard ratio, 0.72; 95% CI, 0.56 to 0.94; p = 0.016) (Fig. s1 in the Supple-
mentary Appendix), and it was consistent with the results reported
previously (Patel et al., 2008). Data from Zhang et al. have revealed
that the induction of TRIB3 by high glucose was reversed to baseline
by euglycemia achieved in vivo and in vitro (Zhang et al., 2015). It is
suggested that the signiﬁcant difference in blood glucose levels between
intensive and standard glucose control groupsmay be a leading cause to
the reverse role of TRIB3 (rs2295490) genetic variation between the two
groups, while the exact mechanism needs to be conﬁrmed by further
research.
For the blood pressure lowering axis, we found that TRIB3
(rs2295490) genetic variation was not signiﬁcantly associated with
the blood pressure response after a ﬁxed combination therapy of
perindopril and indapamide. Interestingly, when taking TRIB3
(rs2295490) AA genotype as the baseline, patients carrying TRIB3
(rs2295490) AG+GGgenotype had a ﬂip effect on diastolic blood pres-
sure response in a ﬁxed combination of perindopril and indapamide
treatment group compared with placebo matching treatment group
(Fig. 4a and b). However, there was no signiﬁcant difference between
AA and AG + GG genotypes in the two groups on the incidence of
majormacrovascular, microvascular, coronary and cerebrovascular out-
comes when analyzed jointly or separately. The more frequent use of
perindopril, calcium channel blockers (CCBs) (57% and 33% at the end
of follow-up, respectively) in the placebo group than the active treat-
ment group (43% and 26% at the end of follow-up, respectively) might
be relevant for such results. Details are shown in Fig. 4a and b.However, in the continuous blood pressure lowering group, irre-
spective of initial blood pressure levels, TRIB3 (rs2295490) G allele car-
riers in the active treatment group got more beneﬁt on coronary events
when compared with placebo group, although the difference was not
signiﬁcant. Limited data (Andreozzi et al., 2008; Zhang et al., 2006;
Leiria et al., 2013; Chan et al., 2007) and our ﬁndings indicate that
TRIB3 mediated signaling pathway may be related to blood pressure
regulation and its genetic variation can affect the response of blood
pressure lowering drugs, subsequently affect cardiovascular event out-
comes. At this point, it is necessary to conduct further study.
Recently, investigation of common genetic variability in type 2 dia-
betes patients with cardiovascular complications from VNDS study
showed that the genetic variations in gatekeepers along the insulin sig-
naling pathway (IRS1, ENPP1 and TRIB3) were associatedwith increased
coronary heart disease (Trombetta et al., 2016). It is suggested that in-
vestigation of genetic variation in other new or key genes, which are re-
lated to insulin signaling pathway may have higher clinical value and
signiﬁcance (Menzaghi et al., 2014; Choi et al., 2016). However, up to
now, the allele gene frequencies of the related genetic variations in
TRIB3 (except rs2295490 mutation) are rare in Chinese population
(b1%). In addition, results from large-scale sequencing did not support
any major role of lower-frequency variants in type 2 diabetes neither
(Fuchsberger et al., 2016). Therefore, we appropriately selected
rs2295490 as candidate single nucleotide polymorphism (SNP) for our
study.
5. Conclusion
In this study, our ﬁndings include: 1) during follow-up period, a par-
tially difference in glucose and blood pressure response were observed
after the intensive and the active treatment between TRIB3 (rs2295490)
AA and AG + GGgenotype, it suggests this gene polymorphism may
have a plausible effect on antidiabetic and antihypertensive drug re-
sponse in patients with T2DM. 2) TRIB3 (rs2295490) genetic variation
was associated with the clinical outcomes of major macrovascular and
microvascular complications in T2DM, while the effects of this genetic
variation has a reverse role between the intensive and standard glucose
control groups, which can be caused by the obvious differences in glu-
cose levels between the two groups. 3) Our ﬁndings suggest that good
glucose and blood pressure control exhibited greater beneﬁts on vascu-
lar outcomes in patients with TRIB3 (rs2295490) G allele.
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